Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of "Hugeltox Inj." in Essential Blepharospasm

Double-blinded, Randomized, Active Control Comparative, Parallel-designed, Phase III Clinical Trial: Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of "Hugeltox Inj." In Essential Blepharospasm Running Parallel With Phase I Study

To compare the efficacy and safety of Hugel-Tox (Botulinum toxin A, Hugel, Korea) against Botox in the treatment of Essential Blepharospasm and to get a regulatory approval from KFDA

Inclusion Criteria:

• Adult between ages 18 and 75 years
• All patients, diagnosed of essential blepharospasm, with Grade 2~4 of Severity of Spmasm (by Scott's Method)

Exclusion Criteria:

• Patients have undergone surgical surgery to treat blepharospmasm like myectomy or neurectomy
• Patients with hypersensitivity history to botulinum toxin products previously
• Patients with secondary blepharomspasm
• Patients with hemifacialspasm
• Patients with treatment following drugs ; Anticonvulsants, tranquilizers, narcotics, aminoglycoside antibiotics, muscle relaxtants like baclofen etc., blockers of parasympathetic nervous system, levodopa
• Patients with previous injection of other botulinum toxin products in 3 months
• Patients with any other significant neuromuscular disease like Myasthenia gravis
• Pregnant or breastfeeding women